SHE:000950

3 stories mentioning SHE:000950Updated 32d ago

Every FINWIRES story that references SHE:000950, newest first.

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

SHA:688443SHE:000950

Asia37d ago

CQ Pharmaceutical Gains China Approval for Hypertension Drug

C.Q. Pharmaceutical (SHE:000950) obtained drug registration from China's medical products regulator for its azilsartan medoxomil potassium tablets.The drug treats primary hypertension, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company closed 1% lower on Monday.

SHE:000950

Asia55d ago

C.Q. Pharmaceutical Unit Gets China Regulatory Nod for Cardiovascular Drug

C.Q. Pharmaceutical (SHE:000950) subsidiary Chongqing Yaoyou Pharmaceutical obtained China's regulatory approval for sodium nitroprusside injection.The drug is indicated for hypertensive emergencies and acute heart failure, according to a Thursday filing with the Shenzhen bourse.

SHE:000950

Track with the FINWIRES app suite

FolioX

Track SHE:000950 in your portfolio

WheelAI

Analyze SHE:000950 options with the wheel strategy

StockInsider

See market sentiment on SHE:000950